Cat. No. 4481
Chemical Name: N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea
Biological ActivityInhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R) (IC50 values are 2, 12, 451 and 217 nM for c-Fms, VEGFR-2, c-Kit and PDGFRβ respectively). Does not inhibit Flt3, EGFR or c-Src. Suppresses ostolysis and osteoclast accumulation induced by metastatic tumor cells.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Ohno et al (2006) A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol.Cancer Ther. 5 2634. PMID: 17121910.
Ohno et al (2007) The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Eur.J.Immunol. 38 283. PMID: 18085662.
Kubota et al (2009) M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J.Exp.Med. 206 1089. PMID: 19398755.
If you know of a relevant citation for this product please let us know.
Keywords: Ki 20227, supplier, Ki20227, c-Fms, macrophage, colony-stimulating, factor, receptors, M-CSFR, CSF1R, inhibitors, inhibits, osteolysis, osteoclast
Find multiple products by catalog number
New Products in this Area
TrkB receptor antagonistR 1530
Multi-RTK inhibitor; inhibits angiogenesisGNF 5837
Potent Trk inhibitor; inhibits TrkA, TrkB and TrkC
Win a Kindle
December 14 - 18, 2013
New Orleans, USA